Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin

Interventions: Other: Description of eosinophilic pneumonia due to daptomycine

Brief Summary: Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria.

Since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in Europe and worldwide.

The purpose of this study is to describe the mechanism of occurrence of this AE with dapto; Prolonged exposure and accumulation at the alveolar level could potentially have a role. Better understanding the mechanisms of appearance of this AE would provide predictive elements making it possible to limit the occurrence of this AE in the future

Detailed Description: Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria.

The Infectious Diseases Society of America recommends the use of daptomycin 6 mg / kg / day in the second-line treatment of IOA on staphylococcal but also enterococcal prostheses, as an alternative to vancomycin and linezolid.

In case of renal failure, daptomycin is often considered as a good therapeutic alternative to glycopeptides.

Since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in Europe and worldwide. Although a large proportion of cases have been reported in patients receiving daptomycin in unapproved indications, the use of daptomycin in authorized indications has also been associated with this risk.

The dosage of daptomycin makes it possible to evaluate its effectiveness and prevent the occurrence of a overdose, provider of side effects.

The purpose of this study is to describe the mechanism of occurrence of this AE with dapto; Prolonged exposure and accumulation at the alveolar level could potentially have a role. Better understanding the mechanisms of appearance of this AE would provide predictive elements making it possible to limit the occurrence of this AE in the future

Recruitment & Eligibility

Inclusion Criteria

patients having had an eosinophilic pneumonia under daptomycine given to treat an osteoarticular infection (BJI/PJI)

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
Eosinophilic pneumonia on daptomycin	Description of eosinophilic pneumonia due to daptomycine	patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia

Primary Outcome Measures

Name	Time	Method
Evalutation of eosinophilic pneumonia due to daptomycin in osteoarticular infection: daptomycine volume distribution	6 months	mean daptomycine volume of distribution (unit, liters)
Evalutation of eosinophilic pneumonia due to daptomycin in osteoarticular infection: duration of daptomycine	6 months	description of the use of daptomycine : duration
Evalutation of eosinophilic pneumonia due to daptomycin in osteoarticular infection: daptomycine plasma clearance	6 months	mean daptomycine plasma clearance (unit, liters per hour)
description of BJI/BJI in patients having eosinophilic pneumonia due to daptomycin	2 months	description of the BJI/PJI (symptoms, type of evolution, type of implant)
description patients having eosinophilic pneumonia due to daptomycin	2 months	description of the patients (average age, medical background)
rate of eosinophilic pneumonia due to daptomycin in osteoarticular infection: the adverse event	6 months	number of cases and description of the adverse event as assessed by CTCAE v4.0
Evalutation of eosinophilic pneumonia due to daptomycin in osteoarticular infection: dosage of daptomycine	6 months	description of the use of daptomycine : dosage

Secondary Outcome Measures

Name	Time	Method